Business Wire

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis

SAN DIEGO--(BUSINESS WIRE)--Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the ...
Nasdaq

Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq:PAHC) and Rejuvenate Bio, Inc. today announced a collaboration for the development and commercialization of a gene therapy for ...
Hosted on MSN

Rejuvenate Biomed doses first subject in COPD-related muscle weakness trial

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01, for treating individuals with muscle weakness and sarcopenia associated with chronic ...
Nasdaq

Phibro Animal Health, Rejuvenate Bio To Develop Gene Therapy For Mitral Valve Disease In Canines

(RTTNews) - Phibro Animal Health Corp. (PAHC) and Rejuvenate Bio Inc. said that they have collaborated to develop and commercialize a gene therapy for Mitral Valve Disease (MVD) in canines (dogs).